Trials / Completed
CompletedNCT00244114
Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients
In Vitro Evaluation Of Allergic Reactions In Hemophilia B Subjects Who Have Exhibited A Systemic Allergic Response After Exposure To BeneFIX (Nonacog Alfa; Recombinant Factor IX)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 20 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Based on the finding that anaphylactic reactions to Benefix ("FIX") are associated with a specific IgE, a Basophil histamine release assay was selected to evaluate and demonstrate subject sensitization to FIX.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | blood draw | Single blood sample collected to perform histamine release assay. |
| PROCEDURE | Blood draw | Single blood sample collected to perform histamine release assay. |
Timeline
- Start date
- 2006-02-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2005-10-25
- Last updated
- 2013-02-18
Source: ClinicalTrials.gov record NCT00244114. Inclusion in this directory is not an endorsement.